Clinical Effectiveness and Cost-effectiveness of Target Therapies for Adult Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer: A Systematic Review

Curr Cancer Drug Targets. 2018;18(5):405-409. doi: 10.2174/1568009617666170206112408.

Abstract

Treatment for advanced non-small cell lung cancer has changed in the last two decades, with many new drugs, mostly target agents, included in the algorithm, improvement of progression free survival and overall survival, but also higher costs for health systems or health insurances. Herein, we analyze the clinical effectiveness of target therapies for non-small cell lung cancer, according to their clinically meaningful outcome criteria and their cost impact.

Keywords: NSCLC; chemotherapy; cost; metastases; prognoses; target agents; therapy..

Publication types

  • Systematic Review

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / economics*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / economics*
  • Carcinoma, Non-Small-Cell Lung / secondary
  • Cost-Benefit Analysis*
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / economics
  • Lung Neoplasms / pathology
  • Molecular Targeted Therapy / economics*
  • Prognosis
  • Treatment Outcome